Noteworthy news from medtech start-ups. This month we profile CardioPolymers Inc., which is developing a highly purified form of seaweed that, when implanted into the heart, has the potential to stop or even reverse the progression of congestive heart failure. We also profile Aura Medsystems, which is developing photodynamic soft-tissue repair technology.
You may also be interested in...
Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.
On roughly the 1-year anniversary of Valisure’s citizen petition to the FDA regarding benzene detected in body sprays, the Personal Care Products Council weighs in on the matter.
Peter Marks says labeling for CSL’s hemophilia B treatment adequately conveys its risks. He also denies NHF request that the label cite eligibility criteria used in clinical trials, responding to a citizen petition on the day the agency approves the therapy.